Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod for inflammatory hand osteoarthritis
ChiCTR2200056416Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iguratimod in hand osteoarthritis and erosive hand osteoarthritis (EHOA), sponsored by Peking University People's Hospital. Primary endpoint: Change in joint pain visual analogue scale at 12 weeks. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
iguratimod
03
Conditions
hand osteoarthritiserosive hand osteoarthritis (EHOA)
Beyond the preview
Go deeper on ChiCTR2200056416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056416.